Cancer Treatment Oncology Genetic Engineering Medical Research Experimental Studies Leukemia Clinical Studies Reality TV Cancer Preclinical Studies
Approved by both companies’ boards, the all-stock acquisition is slated to close in 2025 pending regulatory approval.